

Alexander Y Walley

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/6299517/publications.pdf](https://exaly.com/author-pdf/6299517/publications.pdf)

Version: 2025-02-01

128

PR articles

6,652

PR citations

58710

39

PR h-index

49672

78

g-index

152

documents

8310

doc citations

59108

42

h-index

5781

citing authors

#	ARTICLE	IF	PR CITATIONS
1	PrEP facilitators and barriers in substance use bridge clinics for women who engage in sex work and who use drugs. <i>Addiction Science & Clinical Practice</i> , 2024, 19, .	2.5	3
2	A call for compassionate opioid overdose response. <i>International Journal of Drug Policy</i> , 2024, 133, 104587.	3.4	22
3	The policy landscape for naloxone distribution in four states highly impacted by fatal opioid overdoses. <i>Drug and Alcohol Dependence Reports</i> , 2023, 6, 100126.	1.8	27
4	Perspectives and recommendations of opioid overdose survivors experiencing unsheltered homelessness on housing, overdose, and substance use treatment in Boston, MA. <i>International Journal of Drug Policy</i> , 2023, 119, 104127.	3.4	17
5	The police paradox: A qualitative study of post-overdose outreach program implementation through public health-public safety partnerships in Massachusetts. <i>International Journal of Drug Policy</i> , 2023, 120, 104160.	3.4	19
6	Pharmacists' experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 157-166.	1.8	11
7	Predicting longitudinal service use for individuals with substance use disorders: A latent profile analysis. <i>Journal of Substance Abuse Treatment</i> , 2022, 132, 108632.	2.7	15
8	Warrant checking practices by post-overdose outreach programs in Massachusetts: A mixed-methods study. <i>International Journal of Drug Policy</i> , 2022, 100, 103483.	3.4	22
9	"No home to take methadone to" Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston. <i>Journal of Substance Abuse Treatment</i> , 2022, 135, 108655.	2.7	28
10	Broadening access to naloxone: Community predictors of standing order naloxone distribution in Massachusetts. <i>Drug and Alcohol Dependence</i> , 2022, 230, 109190.	3.0	22
11	Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial. <i>Drug and Alcohol Dependence</i> , 2022, 231, 109259.	3.0	10
12	A collaborative care intervention to improve opioid prescribing among providers caring for persons with HIV: Impact on satisfaction, confidence, and trust. <i>Drug and Alcohol Dependence</i> , 2022, 231, 109250.	3.0	3
13	Variation in Initiation, Engagement, and Retention on Medications for Opioid Use Disorder Based on Health Insurance Plan Design. <i>Medical Care</i> , 2022, 60, 256-263.	1.8	28
14	Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e210-e218.	19.5	99
15	Northeast Postacute Medical Facilities Disproportionately Reject Referrals For Patients With Opioid Use Disorder. <i>Health Affairs</i> , 2022, 41, 434-444.	5.5	22
16	If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study. <i>BMC Public Health</i> , 2022, 22, .	3.3	6
17	Prescribe to Save Lives: Improving Buprenorphine Prescribing Among HIV Clinicians. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 546-552.	1.8	6
18	Functional Impairment and Cognitive Symptoms Among People with HIV Infection on Chronic Opioid Therapy for Pain: The Impact of Gabapentin and Other Sedating Medications. <i>AIDS and Behavior</i> , 2022, , .	2.0	2

#	ARTICLE	IF	PR CITATIONS
19	“There’s No Heroin Around Anymore. It’s All Fentanyl.” Adaptation of an Opioid Overdose Prevention Counseling Approach to Address Fentanyl Overdose: Formative Study. JMIR Formative Research, 2022, 6, e37483.	2.0	16
20	Improving the Delivery of Chronic Opioid Therapy Among People Living With Human Immunodeficiency Virus: A Cluster Randomized Clinical Trial. Clinical Infectious Diseases, 2021, 73, e2052-e2058.	5.4	22
21	Against Medical Advice Discharges in Injection and Non-injection Drug Use-associated Infective Endocarditis: A Nationwide Cohort Study. Clinical Infectious Diseases, 2021, 73, e2484-e2492.	5.4	46
22	Predictors of pain-related functional impairment among people living with HIV on long-term opioid therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 507-515.	1.5	18
23	Emergency Department Utilization Among People Living With HIV on Chronic Opioid Therapy. Journal of the International Association of Providers of AIDS Care, 2021, 20, .	1.7	1
24	Characteristics of post-overdose public health-public safety outreach in Massachusetts. Drug and Alcohol Dependence, 2021, 219, 108499.	3.0	26
25	Projected Estimates of Opioid Mortality After Community-Level Interventions. JAMA Network Open, 2021, 4, e2037259.	6.8	64
26	Competing risks of women and men who use fentanyl: “The number one thing I worry about would be my safety and number two would be overdose.” Journal of Substance Abuse Treatment, 2021, 125, 108313.	2.7	24
27	Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. Drug and Alcohol Dependence, 2021, 224, 108703.	3.0	28
28	Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug and Alcohol Dependence, 2021, 225, 108764.	3.0	55
29	Integrating substance use care into primary care for adolescents and young adults: Lessons learned. Journal of Substance Abuse Treatment, 2021, 129, 108376.	2.7	14
30	Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. International Journal of Drug Policy, 2021, 98, 103435.	3.4	26
31	“It could potentially be dangerous... but nothing else has seemed to help me.” Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment. Journal of Substance Abuse Treatment, 2021, 131, 108455.	2.7	10
32	Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. International Journal of Drug Policy, 2021, 98, 103400.	3.4	15
33	Rejection of Patients With Opioid Use Disorder Referred for Post-acute Medical Care Before and After an Anti-discrimination Settlement in Massachusetts. Journal of Addiction Medicine, 2021, 15, 20-26.	2.1	60
34	Naloxone receipt and overdose prevention care among people with HIV on chronic opioid therapy. Aids, 2021, 35, 697-700.	2.5	2
35	Effect of Publicly Reported Aortic Valve Surgery Outcomes on Valve Surgery in Injection Drug- and Non- Injection Drug-Associated Endocarditis. Clinical Infectious Diseases, 2020, 71, 480-487.	5.4	10
36	Rurality and differences in pharmacy characteristics and community factors associated with provision of naloxone in the pharmacy. International Journal of Drug Policy, 2020, 85, 102602.	3.4	28

#	ARTICLE	IF	PR CITATIONS
37	Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose. <i>Annals of Emergency Medicine</i> , 2020, 75, 29-38.	1.1	35
38	Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 304-310.	1.8	12
39	The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108325.	3.0	108
40	Assessing pharmacy-based naloxone access using an innovative purchase trial methodology. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 853-860.	1.8	20
41	Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waived prescriber supply. <i>Journal of Substance Abuse Treatment</i> , 2020, 115, 108032.	2.7	28
42	Inpatient addiction consultation and post-discharge 30-day acute care utilization. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108081.	3.0	30
43	Opioid overdose and inpatient care for substance use disorder care in Massachusetts. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 42-48.	2.7	24
44	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108335.	3.0	112
45	Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 740-749.	1.8	19
46	Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use—Associated Infective Endocarditis. <i>JAMA Network Open</i> , 2020, 3, e2016228.	6.8	91
47	Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review. <i>Journal of General Internal Medicine</i> , 2020, 35, 2418-2426.	2.8	13
48	Alcohol and Bone Turnover Markers among People Living with HIV and Substance Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 992-1000.	2.6	7
49	Pharmacy leaders'™ beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1493-1497.	2.1	14
50	Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. <i>JAMA Network Open</i> , 2020, 3, e2029676.	6.8	32
51	Chronic Opioid Therapy in People Living With Human Immunodeficiency Virus: Patients'™ Perspectives on Risks, Monitoring, and Guidelines. <i>Clinical Infectious Diseases</i> , 2019, 68, 291-297.	5.4	21
52	Study protocol for the targeting effective analgesia in clinics for HIV (TEACH) study — a cluster randomized controlled trial and parallel cohort to increase guideline concordant care for long-term opioid therapy among people living with HIV. <i>HIV Research and Clinical Practice</i> , 2019, 20, 48-63.	0.9	19
53	Stuck in the Window with You: HIV Exposure Prophylaxis in the Highest Risk People who Inject Drugs. <i>Substance Abuse</i> , 2019, 40, 441-443.	2.5	26
54	Attitudes and perceptions of naloxone dispensing among a sample of Massachusetts community pharmacy technicians. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2019, 59, 824-831.	1.8	19

#	ARTICLE	IF	PR CITATIONS
55	The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015. Public Health Reports, 2019, 134, 667-674.	2.2	31
56	A scoping review of post opioid-overdose interventions. Preventive Medicine, 2019, 128, 105813.	2.9	83
57	Touchpoints “ Opportunities to predict and prevent opioid overdose: A cohort study. Drug and Alcohol Dependence, 2019, 204, 107537.	3.0	164
58	Which patients receive an addiction consult? A preliminary analysis of the INREACH (INpatient) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 35-42.	2.7	17
59	Factors associated with help seeking by community responders trained in overdose prevention and naloxone administration in Massachusetts. Drug and Alcohol Dependence, 2019, 204, 107531.	3.0	23
60	Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug and Alcohol Dependence, 2019, 200, 59-63.	3.0	130
61	Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug and Alcohol Dependence, 2019, 200, 34-39.	3.0	149
62	Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose. Journal of Urban Health, 2019, 96, 367-378.	3.2	47
63	Opioid overdose deaths and potentially inappropriate opioid prescribing practices (PIP): A spatial epidemiological study. International Journal of Drug Policy, 2019, 68, 37-45.	3.4	52
64	Standard Fixed-Schedule Methadone Taper Versus Symptom-Triggered Methadone Approach for Treatment of Neonatal Opioid Withdrawal Syndrome. Hospital Pediatrics, 2019, 9, 576-584.	1.5	14
65	Marijuana Use and Its Associations With Pain, Opioid Dose, and HIV Viral Suppression Among Persons Living With HIV on Chronic Opioid Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 195-201.	1.8	15
66	A strengths-based case management intervention to link HIV-positive people who inject drugs in Russia to HIV care. Aids, 2019, 33, 1467-1476.	2.5	21
67	Provider opioid prescribing practices and the belief that opioids keep people living with HIV engaged in care: a cross-sectional study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 1140-1144.	1.5	13
68	Non-fatal opioid-related overdoses among adolescents in Massachusetts 2012“2014. Drug and Alcohol Dependence, 2019, 194, 28-31.	3.0	34
69	Post opioid overdose outreach by public health and public safety agencies: Exploration of emerging programs in Massachusetts. International Journal of Drug Policy, 2018, 54, 43-50.	3.4	83
70	Expanding access to naloxone for family members: The Massachusetts experience. Drug and Alcohol Review, 2018, 37, 480-486.	2.1	38
71	Massachusetts Health Reform's Effect on Hospitalizations with Substance Use Disorder“Related Diagnoses. Health Services Research, 2018, 53, 1727-1744.	2.1	3
72	Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. Journal of Substance Abuse Treatment, 2018, 85, 90-96.	2.7	300

#	ARTICLE	IF	PR CITATIONS
73	Polypharmacy and risk of falls and fractures for patients with HIV infection and substance dependence. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 150-159.	1.5	29
74	Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts. <i>Obstetrics and Gynecology</i> , 2018, 132, 466-474.	1.4	292
75	Frequency and associated risk factors of non-fatal overdose reported by pregnant women with opioid use disorder. <i>Addiction Science & Clinical Practice</i> , 2018, 13, .	2.5	11
76	Opioid and cocaine use among primary care patients on buprenorphine—Self-report and urine drug tests. <i>Drug and Alcohol Dependence</i> , 2018, 192, 245-249.	3.0	14
77	Estimated Prevalence of Opioid Use Disorder in Massachusetts, 2011—2015: A Capture—Recapture Analysis. <i>American Journal of Public Health</i> , 2018, 108, 1675-1681.	2.9	143
78	Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality. <i>Annals of Internal Medicine</i> , 2018, 169, 137.	10.4	968
79	Alcohol Consumption and Bone Mineral Density in People with HIV and Substance Use Disorder: A Prospective Cohort Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1518-1529.	2.6	17
80	Potentially Inappropriate Opioid Prescribing, Overdose, and Mortality in Massachusetts, 2011—2015. <i>Journal of General Internal Medicine</i> , 2018, 33, 1512-1519.	2.8	59
81	Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know. <i>Addiction Science & Clinical Practice</i> , 2017, 12, .	2.5	144
82	Identification of non-steroidal anti-inflammatory drug use disorder: A case report. <i>Addictive Behaviors</i> , 2017, 70, 61-64.	3.3	15
83	Addiction consultation services — Linking hospitalized patients to outpatient addiction treatment. <i>Journal of Substance Abuse Treatment</i> , 2017, 79, 1-5.	2.7	215
84	HIV-infected individuals who use alcohol and other drugs, and virologic suppression. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1129-1136.	1.5	46
85	HIV Stigma and Substance Use Among HIV-Positive Russians with Risky Drinking. <i>AIDS and Behavior</i> , 2017, 21, 2618-2627.	2.0	13
86	Fatal and non-fatal overdose after narcology hospital discharge among Russians living with HIV/AIDS who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 39, 114-120.	3.4	6
87	Polypharmacy and risk of non-fatal overdose for patients with HIV infection and substance dependence. <i>Journal of Substance Abuse Treatment</i> , 2017, 81, 1-10.	2.7	15
88	Characteristics of Fentanyl Overdose — Massachusetts, 2014—2016. <i>Morbidity and Mortality Weekly Report</i> , 2017, 66, 382-386.	11.7	273
89	Sexual violence from police and HIV risk behaviours among HIV—positive women who inject drugs in St. Petersburg, Russia—A mixed methods study. <i>Journal of the International AIDS Society</i> , 2016, 19, .	3.6	23
90	Why is it so hard to implement change? A qualitative examination of barriers and facilitators to distribution of naloxone for overdose prevention in a safety net environment. <i>BMC Research Notes</i> , 2016, 9, .	1.4	61

#	ARTICLE	IF	PR CITATIONS
91	Mortality in HIV-Infected Alcohol and Drug Users in St. Petersburg, Russia. PLoS ONE, 2016, 11, e0166539.	2.4	13
92	Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist. Postgraduate Medical Journal, 2016, 92, 356-363.	2.2	32
93	Comments on Strang et al. (2016): "Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?" Addiction, 2016, 111, 1879-1880.	5.4	1
94	Identifying Patients for Overdose Prevention With ICD-9 Classification in the Emergency Department, Massachusetts, 2013-2014. Public Health Reports, 2016, 131, 671-675.	2.2	24
95	Lessons Learned from the Expansion of Naloxone Access in Massachusetts and North Carolina. Journal of Law, Medicine and Ethics, 2015, 43, 19-22.	0.7	22
96	Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduction Journal, 2015, 12, .	3.1	99
97	Opioid Education and Nasal Naloxone Rescue Kits in the Emergency Department. Western Journal of Emergency Medicine, 2015, 16, 381-384.	0.8	136
98	Engagement and Substance Dependence in a Primary Care-Based Addiction Treatment Program for People Infected with HIV and People at High-Risk for HIV Infection. Journal of Substance Abuse Treatment, 2015, 59, 59-66.	2.7	42
99	A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming into Clinical Practice. Substance Abuse, 2015, 36, 240-253.	2.5	164
100	Punitive policing and associated substance use risks among HIV-positive people in Russia who inject drugs. Journal of the International AIDS Society, 2014, 17, .	3.6	37
101	Patient Perspectives of an Integrated Program of Medical Care and Substance Use Treatment. AIDS Patient Care and STDs, 2014, 28, 71-81.	2.8	74
102	Prenatal Buprenorphine Versus Methadone Exposure and Neonatal Outcomes: Systematic Review and Meta-Analysis. American Journal of Epidemiology, 2014, 180, 673-686.	3.4	157
103	Emergency Medical Services Naloxone Access: A National Systematic Legal Review. Academic Emergency Medicine, 2014, 21, 1173-1177.	1.7	80
104	Development and Implementation of an Opioid Overdose Prevention Program Within a Preexisting Substance Use Disorders Treatment Center. Journal of Addiction Medicine, 2014, 8, 164-169.	2.1	8
105	Postpartum changes in methadone maintenance dose. Journal of Substance Abuse Treatment, 2014, 47, 229-232.	2.7	18
106	Risk factors for recent nonfatal overdose among HIV-infected Russians who inject drugs. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 1013-1018.	1.5	12
107	Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health, 2014, 14, .	3.3	143
108	Expanded Access to Naloxone Among Firefighters, Police Officers, and Emergency Medical Technicians in Massachusetts. American Journal of Public Health, 2014, 104, e7-e9.	2.9	135

#	ARTICLE	IF	PR CITATIONS
109	Heroin Use and HIV Disease Progression: Results from a Pilot Study of a Russian Cohort. <i>AIDS and Behavior</i> , 2014, 19, 1089-1097.	2.0	9
110	2012 Update in addiction medicine for the generalist. <i>Addiction Science & Clinical Practice</i> , 2013, 8, .	2.5	4
111	2013 Update in addiction medicine for the generalist. <i>Addiction Science & Clinical Practice</i> , 2013, 8, .	2.5	4
112	Opioid overdose prevention with intranasal naloxone among people who take methadone. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 241-247.	2.7	96
113	Is cannabis use associated with HIV drug and sex risk behaviors among Russian HIV-infected risky drinkers?. <i>Drug and Alcohol Dependence</i> , 2013, 132, 74-80.	3.0	21
114	Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. <i>BMJ, The</i> , 2013, 346, f174-f174.	0.2	849
115	Methadone Dose, Take Home Status, and Hospital Admission Among Methadone Maintenance Patients. <i>Journal of Addiction Medicine</i> , 2012, 6, 186-190.	2.1	39
116	Acute Care Hospital Utilization Among Medical Inpatients Discharged With a Substance Use Disorder Diagnosis. <i>Journal of Addiction Medicine</i> , 2012, 6, 50-56.	2.1	139
117	Nondisclosure of HIV Infection to Sex Partners and Alcohol's Role: A Russian Experience. <i>AIDS and Behavior</i> , 2012, 17, 390-398.	2.0	21
118	Update in Addiction Medicine for the Generalist. <i>Journal of General Internal Medicine</i> , 2010, 26, 77-82.	2.8	7
119	Are Opioid Dependence and Methadone Maintenance Treatment (MMT) Documented in the Medical Record? A Patient Safety Issue. <i>Journal of General Internal Medicine</i> , 2009, 24, 1007-1011.	2.8	16
120	The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. <i>Drug and Alcohol Dependence</i> , 2009, 101, 101-106.	3.0	57
121	Saved by the Nose: Bystander-Administered Intranasal Naloxone Hydrochloride for Opioid Overdose. <i>American Journal of Public Health</i> , 2009, 99, 788-791.	2.9	224
122	Office-Based Management of Opioid Dependence with Buprenorphine: Clinical Practices and Barriers. <i>Journal of General Internal Medicine</i> , 2008, 23, 1393-1398.	2.8	201
123	[Commentary] CAN ONE BE AN EXPERT IN ADDICTION MEDICINE WITHOUT EXPERTISE IN PAIN MANAGEMENT?. <i>Addiction</i> , 2008, 103, 2006-2007.	5.4	4
124	The Patients in Recovery (PIR) Perspective: Teaching Physicians about Methamphetamine. <i>Substance Abuse</i> , 2008, 29, 61-64.	2.5	2
125	Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. <i>Aids</i> , 2008, 22, 415-420.	2.5	43
126	Implications of Cannabis Use and Heavy Alcohol Use on HIV Drug Risk Behaviors in Russian Heroin Users. <i>AIDS and Behavior</i> , 2007, 12, 662-669.	2.0	12

#	ARTICLE	IF	PR CITATIONS
127	Knowledge of and interest in hepatitis C treatment at a methadone clinic. Journal of Substance Abuse Treatment, 2005, 28, 181-187.	2.7	72
128	Title is missing!. Journal of Community Health, 2000, 25, 315-329.	1.9	10